ATR and neuroendocrine carcinoma: Further investigation would also be warranted whether neuroendocrine cancers where ribosome biogenesis is impaired would respond to combination treatment of IMPDH and ATR inhibitors which predominantly generates RS leading to cellular cytotoxicity as demonstrated in the present study.